Nucletron and ART jointly announce a Global Strategic Partnership





Nucletron, a knowledge-based leader in radiation oncology, and Advanced Radiation Therapy (ART) announced an exclusive global, strategic partnership to offer the AccuBoostsystem with the microSelectron high-dose rate (HDR) brachytherapy afterloader treatment delivery solution for the treatment of breast cancer.

 
The partnership offers radiation oncology centers the opportunity to implement ART’s innovative technology in image-guided HDR breast brachytherapy on a pay-per-patient pricing model, along with a full complement of Nucletron’s treatment planning, treatment delivery, training, licensing, reimbursement, and customized service support. ART’s expansion of AccuBoost technology through its global partnership with Nucletron will further reduce the barriers to adoption of brachytherapy for cancer centers previously deterred by the initial start-up costs usually associated with implementing a breast brachytherapy program.

Jos Lamers, chief executive officer for Nucletron said, we are thrilled to partner with ART and expand the availability and utilization of HDR brachytherapy globally. Using Nucletron’s microSelectron Digital afterloader to deliver AccuBoost technology further reduces the financial, operational, and clinical barriers many cancer centers encounter in providing brachytherapy to their patients. In conjunction with this announcement, Nucletron is offering a pay-per-patient pricing model for centers bundling the AccuBoost treatment option with their new HDR brachytherapy program, allowing these centers to pay for the service when the boost treatment is delivered, providing a more attractive financing model while delivering more treatment options to their patients.